Cardiac dysfunction in medulloblastoma survivors treated with photon irradiation.
ECHO surveillance
cardiac toxicity
echocardiogram
pediatric brain tumor
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Medulloblastoma is an aggressive central nervous system (CNS) tumor that occurs mostly in the pediatric population. Treatment often includes a combination of surgical resection, craniospinal irradiation (CSI), and chemotherapy. Children who receive standard photon CSI are at risk for cardiac toxicities including coronary artery disease, left ventricular scarring and dysfunction, valvular damage, and atherosclerosis. Current survivorship guidelines recommend routine echocardiogram (ECHO) surveillance. In this multi-institutional study, we describe markers of cardiac dysfunction in medulloblastoma survivors. A retrospective chart review of medulloblastoma patients who had photon beam CSI was followed by ECHO between 1980 and 2010 at Lurie Children's Hospital and Dana-Farber/Boston Children's Hospital. During the 30-year study period, 168 medulloblastoma patient records were identified. Included in this study were the 75 patients who received CSI or spinal radiation and ECHO follow-up. The mean age at CSI was 8.6 years (range, 2.9-20), and the mean number of years between radiation therapy (RT) completion and first ECHO was 7.4 (range, 2-16). Mean ejection fraction (EF) was 60.0% and shortening fraction (SF) was 33.8%. Five patients (7%) had abnormal ECHO results: three with EF <50% and two with SF <28%. The majority of medulloblastoma patients who received CSI have relatively normal ECHOs post-treatment; however, 7% of patients had abnormal ECHOs. The implication of our study for medulloblastoma survivors is that further investigations are needed in this population with a more systematic, longitudinal assessment to determine predictors and screenings.
Sections du résumé
Background
UNASSIGNED
Medulloblastoma is an aggressive central nervous system (CNS) tumor that occurs mostly in the pediatric population. Treatment often includes a combination of surgical resection, craniospinal irradiation (CSI), and chemotherapy. Children who receive standard photon CSI are at risk for cardiac toxicities including coronary artery disease, left ventricular scarring and dysfunction, valvular damage, and atherosclerosis. Current survivorship guidelines recommend routine echocardiogram (ECHO) surveillance. In this multi-institutional study, we describe markers of cardiac dysfunction in medulloblastoma survivors.
Methods
UNASSIGNED
A retrospective chart review of medulloblastoma patients who had photon beam CSI was followed by ECHO between 1980 and 2010 at Lurie Children's Hospital and Dana-Farber/Boston Children's Hospital.
Results
UNASSIGNED
During the 30-year study period, 168 medulloblastoma patient records were identified. Included in this study were the 75 patients who received CSI or spinal radiation and ECHO follow-up. The mean age at CSI was 8.6 years (range, 2.9-20), and the mean number of years between radiation therapy (RT) completion and first ECHO was 7.4 (range, 2-16). Mean ejection fraction (EF) was 60.0% and shortening fraction (SF) was 33.8%. Five patients (7%) had abnormal ECHO results: three with EF <50% and two with SF <28%.
Conclusion
UNASSIGNED
The majority of medulloblastoma patients who received CSI have relatively normal ECHOs post-treatment; however, 7% of patients had abnormal ECHOs. The implication of our study for medulloblastoma survivors is that further investigations are needed in this population with a more systematic, longitudinal assessment to determine predictors and screenings.
Identifiants
pubmed: 35859541
doi: 10.1093/nop/npac030
pii: npac030
pmc: PMC9290868
doi:
Types de publication
Journal Article
Langues
eng
Pagination
338-343Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Biomed Res Int. 2016;2016:9363951
pubmed: 26942202
Cardiooncology. 2019 Oct 23;5:16
pubmed: 32154022
J Am Coll Cardiol. 2021 Jun 1;77(21):2693-2716
pubmed: 34045027
J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8
pubmed: 10379968
Eur Heart J. 2014 Mar;35(10):612-23
pubmed: 23666251
J Pediatr Hematol Oncol. 2015 Oct;37(7):e405-11
pubmed: 26334433
Curr Opin Pediatr. 2007 Aug;19(4):480-7
pubmed: 17630615
Pediatr Blood Cancer. 2013 Dec;60(12):1982-7
pubmed: 23897631
Pediatr Blood Cancer. 2009 Jul;52(7):853-9
pubmed: 19165891
JAMA Netw Open. 2018 Aug 3;1(4):e181456
pubmed: 30646130
J Egypt Natl Canc Inst. 2015 Dec;27(4):187-93
pubmed: 26296945
Cardiol Young. 2019 Dec;29(12):1494-1500
pubmed: 31771663
AJR Am J Roentgenol. 1997 Apr;168(4):1011-5
pubmed: 9124106
Nat Rev Cardiol. 2015 Sep;12(9):547-58
pubmed: 25962976
J Clin Oncol. 2013 Oct 10;31(29):3673-80
pubmed: 24002505
Am J Med Sci. 2016 Jun;351(6):570-5
pubmed: 27238918
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
J Natl Cancer Inst. 2009 Jul 1;101(13):946-58
pubmed: 19535780
J Am Soc Echocardiogr. 2019 Oct;32(10):1331-1338.e1
pubmed: 31351792
J Pediatr Hematol Oncol. 2016 Jan;38(1):27-31
pubmed: 26422286
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):277-84
pubmed: 23433794
Lancet Oncol. 2016 Mar;17(3):287-298
pubmed: 26830377
Pediatrics. 1992 May;89(5 Pt 1):942-9
pubmed: 1579408
Crit Rev Oncol Hematol. 2018 Jun;126:186-200
pubmed: 29759560
J Int Neuropsychol Soc. 2013 Jan;19(1):44-53
pubmed: 23095276
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5
pubmed: 8768873
J Investig Med. 2019 Feb;67(2):295-302
pubmed: 30530528
Pediatr Blood Cancer. 2014 Dec;61(12):2319-20
pubmed: 25154390
J Clin Oncol. 2011 Dec 20;29(36):4776-80
pubmed: 22042949
Rep Pract Oncol Radiother. 2010 Feb 18;15(1):21-4
pubmed: 24376918
Cancer Treat Rev. 2009 Nov;35(7):616-32
pubmed: 19640651
J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79
pubmed: 18812549
J Child Neurol. 2009 Nov;24(11):1455-63
pubmed: 19841433
J Clin Oncol. 2005 Oct 20;23(30):7685-96
pubmed: 16234530
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1913-9
pubmed: 24962841
Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):817-832
pubmed: 28679288
Cancer J. 2004 Nov-Dec;10(6):386-90
pubmed: 15701271
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):727-34
pubmed: 14967427
Pediatr Cardiol. 2015 Dec;36(8):1610-6
pubmed: 26049414
J Thromb Thrombolysis. 2021 May;51(4):877-883
pubmed: 33033980
Arch Intern Med. 2010 Jul 26;170(14):1247-55
pubmed: 20660845
N Engl J Med. 1991 Mar 21;324(12):808-15
pubmed: 1997853
Endocr Dev. 2009;15:1-24
pubmed: 19293601
Cardiooncology. 2021 Feb 2;7(1):5
pubmed: 33531084